RU2403258C2 - Тиазолилдигидроиндазолы - Google Patents
Тиазолилдигидроиндазолы Download PDFInfo
- Publication number
- RU2403258C2 RU2403258C2 RU2007116858/04A RU2007116858A RU2403258C2 RU 2403258 C2 RU2403258 C2 RU 2403258C2 RU 2007116858/04 A RU2007116858/04 A RU 2007116858/04A RU 2007116858 A RU2007116858 A RU 2007116858A RU 2403258 C2 RU2403258 C2 RU 2403258C2
- Authority
- RU
- Russia
- Prior art keywords
- nitrogen
- group
- oxygen
- compounds
- phenyl
- Prior art date
Links
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract 33
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 23
- 125000005842 heteroatom Chemical group 0.000 claims abstract 21
- 150000001875 compounds Chemical class 0.000 claims abstract 17
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract 13
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 13
- 239000001301 oxygen Substances 0.000 claims abstract 13
- 125000001424 substituent group Chemical group 0.000 claims abstract 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 11
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims abstract 10
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 9
- 239000001257 hydrogen Substances 0.000 claims abstract 9
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 7
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims abstract 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 6
- 229940116355 PI3 kinase inhibitor Drugs 0.000 claims abstract 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract 6
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 claims abstract 6
- 239000003814 drug Substances 0.000 claims abstract 5
- 150000003839 salts Chemical class 0.000 claims abstract 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 4
- 238000002360 preparation method Methods 0.000 claims abstract 3
- 230000015572 biosynthetic process Effects 0.000 claims abstract 2
- 229940079593 drug Drugs 0.000 claims abstract 2
- 229910052736 halogen Inorganic materials 0.000 claims abstract 2
- 150000002367 halogens Chemical class 0.000 claims abstract 2
- 150000002431 hydrogen Chemical class 0.000 claims abstract 2
- 239000013067 intermediate product Substances 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 238000003786 synthesis reaction Methods 0.000 claims abstract 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 9
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 claims 5
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 239000011593 sulfur Chemical group 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000006187 phenyl benzyl group Chemical group 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 6
- 239000005864 Sulphur Substances 0.000 abstract 3
- 125000004429 atom Chemical group 0.000 abstract 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 abstract 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/84—Naphthothiazoles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004048877A DE102004048877A1 (de) | 2004-10-07 | 2004-10-07 | PI3-Kinasen |
| DE102004048877.0 | 2004-10-07 | ||
| DE102005005813A DE102005005813A1 (de) | 2005-02-09 | 2005-02-09 | PI3-Kinasen |
| DE102005005813.2 | 2005-02-09 | ||
| EP05107230.4 | 2005-08-05 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2007116858A RU2007116858A (ru) | 2008-12-27 |
| RU2403258C2 true RU2403258C2 (ru) | 2010-11-10 |
Family
ID=35583390
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007116858/04A RU2403258C2 (ru) | 2004-10-07 | 2005-10-05 | Тиазолилдигидроиндазолы |
| RU2007116861/04A RU2007116861A (ru) | 2004-10-07 | 2005-10-05 | P13-киназы |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007116861/04A RU2007116861A (ru) | 2004-10-07 | 2005-10-05 | P13-киназы |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US7691888B2 (enExample) |
| EP (2) | EP1802636B1 (enExample) |
| JP (1) | JP5122287B2 (enExample) |
| KR (1) | KR20070064660A (enExample) |
| CN (1) | CN101048418A (enExample) |
| AR (1) | AR055273A1 (enExample) |
| AU (1) | AU2005293607A1 (enExample) |
| BR (1) | BRPI0516557A (enExample) |
| CA (1) | CA2579279C (enExample) |
| IL (1) | IL182398A0 (enExample) |
| MX (1) | MX2007004051A (enExample) |
| RU (2) | RU2403258C2 (enExample) |
| TW (1) | TW200628475A (enExample) |
| WO (1) | WO2006040279A1 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050096332A1 (en) * | 2003-10-30 | 2005-05-05 | Boehringer Ingelheim International Gmbh | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes |
| AU2005293607A1 (en) * | 2004-10-07 | 2006-04-20 | Boehringer Ingelheim International Gmbh | PI3 kinases |
| US7691868B2 (en) | 2006-04-06 | 2010-04-06 | Boehringer Ingelheim International Gmbh | Thiazolyl-dihydro-quinazoline |
| US20070238746A1 (en) * | 2006-04-06 | 2007-10-11 | Trixi Brandl | Thiazolyl-dihydro-chinazoline |
| US20070238718A1 (en) * | 2006-04-06 | 2007-10-11 | Matthias Grauert | Thiazolyl-dihydro-indazole |
| MX2008012535A (es) * | 2006-04-06 | 2008-10-10 | Boehringer Ingelheim Int | Tiazolil-dihidro-indazoles. |
| US7517995B2 (en) * | 2006-04-06 | 2009-04-14 | Boehringer Ingelheim International Gmbh | Thiazolyl-dihydro-cyclopentapyrazole |
| US20070259855A1 (en) * | 2006-04-06 | 2007-11-08 | Udo Maier | Thiazolyl-dihydro-indazole |
| DE602006002385D1 (de) * | 2006-06-26 | 2008-10-02 | Helm Ag | Verfahren zur Herstellung von Pramipexole |
| EP2045253A4 (en) * | 2006-06-29 | 2013-01-23 | Nissan Chemical Ind Ltd | alpha-amino acid derivative and pharmaceutical agent containing it as an active ingredient |
| US8779154B2 (en) | 2006-09-26 | 2014-07-15 | Qinglin Che | Fused ring compounds for inflammation and immune-related uses |
| GB0619611D0 (en) * | 2006-10-04 | 2006-11-15 | Ark Therapeutics Ltd | Compounds and their use |
| WO2009039140A1 (en) * | 2007-09-17 | 2009-03-26 | Smithkline Beecham Corporation | Pyridopyrimidine derivatives as pi3 kinase inhibitors |
| US20110052643A1 (en) * | 2008-01-07 | 2011-03-03 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
| PE20091617A1 (es) * | 2008-03-13 | 2009-11-12 | Boehringer Ingelheim Int | Tiazolil-dihidro-indazoles |
| WO2009120826A1 (en) * | 2008-03-27 | 2009-10-01 | Wyeth | 2-aryl- and 2-heteroarylthiazolyl compounds, methods for their preparation and use thereof |
| RU2506267C2 (ru) | 2008-03-31 | 2014-02-10 | Дженентек, Инк. | Бензопирановые и бензоксепиновые ингибиторы рi3k и их применение |
| WO2010007943A1 (ja) * | 2008-07-17 | 2010-01-21 | 旭化成ファーマ株式会社 | 含窒素複素環化合物 |
| US20110230472A1 (en) * | 2008-08-29 | 2011-09-22 | Shionogi & Co., Ltd. | Ring-fused azole derivative having pi3k-inhibiting activity |
| EP2350084B1 (en) * | 2008-10-17 | 2015-06-24 | Boehringer Ingelheim International GmbH | Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (pi3-kinases) inhibitor |
| GB0900404D0 (en) | 2009-01-12 | 2009-02-11 | Addex Pharmaceuticals Sa | New compounds 4 |
| US8278302B2 (en) | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| EP2421872B1 (en) * | 2009-04-22 | 2015-06-10 | Boehringer Ingelheim International GmbH | Thia-triaza-as-indacenes as pi3-kinases inhibitors for the treatment of cancer |
| US8288379B2 (en) | 2009-04-22 | 2012-10-16 | Boehringer Ingelheim International Gmbh | Thia-triaza-cyclopentazulenes |
| ES2432671T3 (es) * | 2009-07-02 | 2013-12-04 | Novartis Ag | 2-carboxamida cicloamino ureas útiles como inhibidores de PI3K |
| UA111579C2 (uk) | 2009-08-17 | 2016-05-25 | Інтеллікіне Ллк | ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ |
| EP2483277B1 (en) * | 2009-09-28 | 2015-12-02 | F. Hoffmann-La Roche AG | Benzoxepin pi3k inhibitor compounds and methods of use |
| EP2845592A1 (en) * | 2009-09-28 | 2015-03-11 | F. Hoffmann-La Roche AG | Benzoxazepin PI3K inhibitor compounds and methods of use |
| CN102695710B (zh) * | 2009-11-13 | 2015-08-19 | 默克雪兰诺有限公司 | 三环吡唑胺衍生物 |
| CN103153062B (zh) | 2010-05-24 | 2015-07-15 | 因特利凯有限责任公司 | 杂环化合物及其用途 |
| US20130252944A1 (en) * | 2010-07-14 | 2013-09-26 | Christelle Bolea | Novel fused pyrazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
| GB201011831D0 (en) | 2010-07-14 | 2010-09-01 | Addex Pharmaceuticals Sa | New compounds 5 |
| TW201245176A (en) | 2011-01-26 | 2012-11-16 | Boehringer Ingelheim Int | New 5-alkynyl-pyridines |
| EP2546249A1 (en) | 2011-07-15 | 2013-01-16 | Boehringer Ingelheim International Gmbh | 5-Alkynyl-pyridines |
| US8466162B2 (en) | 2011-01-26 | 2013-06-18 | Boehringer Ingelheim International Gmbh | 5-alkynyl-pyridines |
| TWI592411B (zh) | 2011-02-23 | 2017-07-21 | 英特爾立秦有限責任公司 | 激酶抑制劑之組合及其用途 |
| EP2678016B1 (en) | 2011-02-23 | 2016-08-10 | Intellikine, LLC | Heterocyclic compounds and uses thereof |
| RU2013143747A (ru) | 2011-03-21 | 2015-04-27 | Ф. Хоффманн-Ля Рош Аг | Соединения бензоксазепина, селективные в отношении pi3k p110 дельта и способы их применения |
| CA2861496A1 (en) * | 2012-02-06 | 2013-08-15 | Glaxosmithkline Intellectual Property (No.2) Limited | Pi3k inhibitors for treating cough |
| WO2017156350A1 (en) | 2016-03-09 | 2017-09-14 | K-Gen, Inc. | Methods of cancer treatment |
| JP7768505B2 (ja) | 2018-06-01 | 2025-11-12 | コーネル・ユニバーシティー | Pi3kに関連する疾患または障害に対する併用療法 |
| US11174263B2 (en) | 2018-12-31 | 2021-11-16 | Biomea Fusion, Inc. | Inhibitors of menin-MLL interaction |
| AU2019417833B2 (en) | 2018-12-31 | 2024-11-07 | Biomea Fusion, Inc. | Irreversible inhibitors of menin-MLL interaction |
| CA3228627A1 (en) | 2021-08-11 | 2023-02-16 | Thomas Butler | Covalent inhibitors of menin-mll interaction for diabetes mellitus |
| EP4387972A1 (en) | 2021-08-20 | 2024-06-26 | Biomea Fusion, Inc. | Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo -2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-mll inhibitor for the treatment of cancer |
| WO2024155710A1 (en) | 2023-01-18 | 2024-07-25 | Biomea Fusion, Inc. | Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6- yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2-pyridinecarboxamide as a covalent inhibitor of menin-mll interaction |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2125053C1 (ru) * | 1994-03-28 | 1999-01-20 | Ниссан Кемикал Индастриз Лтд. (JP | Соединение тиазолидина пиридинового типа или его соль, гипогликемическое средство, антигликационное средство и фармацевтическое средство, ингибирующее гипергликемию, неферментативную гликацию и альдозоредуктазу, для предупреждения и лечения сахарного диабета и диабетических осложнений |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5533405A (en) | 1978-08-29 | 1980-03-08 | Teijin Ltd | Hexahydronaphtho(1',2':4,5)imidazo(2,1-b)thiazole and its preparation |
| WO1979001080A1 (fr) | 1978-05-17 | 1979-12-13 | Teijin Ltd | Hexahydronaphtoimidazothiazoles et procede pour leur preparation |
| ATE45735T1 (de) * | 1984-12-22 | 1989-09-15 | Thomae Gmbh Dr K | Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arnzneimittel. |
| US5358949A (en) * | 1986-03-05 | 1994-10-25 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives |
| US5182290A (en) * | 1991-08-27 | 1993-01-26 | Neurogen Corporation | Certain oxazoloquinolinones; a new class of GABA brain receptor ligands |
| TW260664B (enExample) * | 1993-02-15 | 1995-10-21 | Otsuka Pharma Factory Inc | |
| JP3670309B2 (ja) | 1993-04-01 | 2005-07-13 | 第一製薬株式会社 | 二環性複素環化合物 |
| NO941135L (no) | 1993-04-01 | 1994-10-03 | Daiichi Seiyaku Co | Tiazolpyrimidin derivater |
| AU727654B2 (en) * | 1997-06-13 | 2000-12-21 | Yamanouchi Pharmaceutical Co., Ltd. | Tricyclic pyrazole derivative |
| US7091227B2 (en) * | 2000-02-07 | 2006-08-15 | Abbott Gmbh & Co. Kg | Benzothiazole derivatives |
| HUP0300382A3 (en) * | 2000-03-29 | 2006-11-28 | Cyclacel Ltd | 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders and pharmaceutical compositions containing the compounds |
| US6608053B2 (en) * | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| KR100423899B1 (ko) * | 2000-05-10 | 2004-03-24 | 주식회사 엘지생명과학 | 세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸 |
| US6908932B2 (en) | 2001-10-24 | 2005-06-21 | Iconix Pharmaceuticals, Inc. | Modulators of phosphoinositide 3-kinase |
| MY156407A (en) * | 2002-02-28 | 2016-02-26 | Novartis Ag | 5-phenylthiazole derivatives and use as p13 kinase inhibitors |
| EP1349179A1 (en) * | 2002-03-18 | 2003-10-01 | ATOFINA Research | Conductive polyolefins with good mechanical properties |
| CA2493843C (en) | 2002-07-10 | 2012-04-17 | Applied Research Systems Ars Holding N.V. | Azolidinone-vinyl fused-benzene derivatives |
| ATE411996T1 (de) | 2002-09-30 | 2008-11-15 | Bayer Healthcare Ag | Kondensierte azolpyrimidinderivate |
| JP2006510661A (ja) | 2002-12-06 | 2006-03-30 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | Pi3kの阻害剤としてのベンズオキサジン−3−オン類及びその誘導体 |
| WO2004056820A1 (en) | 2002-12-20 | 2004-07-08 | Warner-Lambert Company Llc | Benzoxazines and derivatives thereof as inhibitors of pi3ks |
| GB0315966D0 (en) * | 2003-07-08 | 2003-08-13 | Cyclacel Ltd | Compounds |
| NO20041733L (no) * | 2004-04-28 | 2005-10-31 | Thin Film Electronics Asa | Organisk elektronisk krets med funksjonelt mellomsjikt og fremgangsmate til dens fremstilling. |
| AU2005293607A1 (en) * | 2004-10-07 | 2006-04-20 | Boehringer Ingelheim International Gmbh | PI3 kinases |
| FR2887993B1 (fr) * | 2005-07-01 | 2007-08-03 | Commissariat Energie Atomique | Dispositif de detection de rayonnements a electrodes empilees et methode de detection de rayonnements ionisants mettant en oeuvre un tel dispositif |
| US20070259855A1 (en) * | 2006-04-06 | 2007-11-08 | Udo Maier | Thiazolyl-dihydro-indazole |
| BRPI0710841A2 (pt) * | 2006-04-06 | 2011-08-23 | Boehringer Ingelheim Int | compostos derivados de tiazolil dihidroindazóis como inibidores da proteìna quinase, preparações farmacêuticas e o uso das mesmas |
-
2005
- 2005-10-05 AU AU2005293607A patent/AU2005293607A1/en not_active Abandoned
- 2005-10-05 RU RU2007116858/04A patent/RU2403258C2/ru not_active IP Right Cessation
- 2005-10-05 RU RU2007116861/04A patent/RU2007116861A/ru not_active Application Discontinuation
- 2005-10-05 EP EP05805652A patent/EP1802636B1/de not_active Expired - Lifetime
- 2005-10-05 EP EP11158787A patent/EP2343303A1/de not_active Withdrawn
- 2005-10-05 KR KR1020077010387A patent/KR20070064660A/ko not_active Withdrawn
- 2005-10-05 WO PCT/EP2005/055015 patent/WO2006040279A1/de not_active Ceased
- 2005-10-05 US US11/243,796 patent/US7691888B2/en not_active Expired - Lifetime
- 2005-10-05 BR BRPI0516557-1A patent/BRPI0516557A/pt not_active IP Right Cessation
- 2005-10-05 MX MX2007004051A patent/MX2007004051A/es not_active Application Discontinuation
- 2005-10-05 CN CNA2005800344060A patent/CN101048418A/zh active Pending
- 2005-10-05 CA CA2579279A patent/CA2579279C/en not_active Expired - Lifetime
- 2005-10-05 JP JP2007535159A patent/JP5122287B2/ja not_active Expired - Lifetime
- 2005-10-05 US US11/244,299 patent/US20060106013A1/en not_active Abandoned
- 2005-10-06 TW TW094134899A patent/TW200628475A/zh unknown
- 2005-10-07 AR ARP050104225A patent/AR055273A1/es unknown
-
2007
- 2007-04-10 IL IL182398A patent/IL182398A0/en unknown
-
2009
- 2009-02-05 US US12/366,248 patent/US8232286B2/en active Active
-
2010
- 2010-01-11 US US12/685,213 patent/US8207349B2/en not_active Expired - Lifetime
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2125053C1 (ru) * | 1994-03-28 | 1999-01-20 | Ниссан Кемикал Индастриз Лтд. (JP | Соединение тиазолидина пиридинового типа или его соль, гипогликемическое средство, антигликационное средство и фармацевтическое средство, ингибирующее гипергликемию, неферментативную гликацию и альдозоредуктазу, для предупреждения и лечения сахарного диабета и диабетических осложнений |
Also Published As
| Publication number | Publication date |
|---|---|
| US20090156554A1 (en) | 2009-06-18 |
| AU2005293607A1 (en) | 2006-04-20 |
| EP1802636B1 (de) | 2013-03-27 |
| US20100113414A1 (en) | 2010-05-06 |
| US20060100254A1 (en) | 2006-05-11 |
| WO2006040279A1 (de) | 2006-04-20 |
| JP2008515852A (ja) | 2008-05-15 |
| TW200628475A (en) | 2006-08-16 |
| CA2579279C (en) | 2013-10-01 |
| US20060106013A1 (en) | 2006-05-18 |
| MX2007004051A (es) | 2007-05-24 |
| KR20070064660A (ko) | 2007-06-21 |
| AR055273A1 (es) | 2007-08-15 |
| CN101048418A (zh) | 2007-10-03 |
| RU2007116858A (ru) | 2008-12-27 |
| CA2579279A1 (en) | 2006-04-20 |
| BRPI0516557A (pt) | 2008-09-09 |
| IL182398A0 (en) | 2007-07-24 |
| JP5122287B2 (ja) | 2013-01-16 |
| US8232286B2 (en) | 2012-07-31 |
| EP2343303A1 (de) | 2011-07-13 |
| EP1802636A1 (de) | 2007-07-04 |
| US8207349B2 (en) | 2012-06-26 |
| RU2007116861A (ru) | 2009-03-20 |
| US7691888B2 (en) | 2010-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2403258C2 (ru) | Тиазолилдигидроиндазолы | |
| RU2350605C2 (ru) | Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ | |
| RU2495044C2 (ru) | Ингибиторы активности протеинтирозинкиназы | |
| RU2397168C2 (ru) | Производные тиофена в качестве ингибиторов снк 1 | |
| RU2404979C2 (ru) | 2,4-ди(аминофенил)пиримидины в качестве ингибиторов рlk-киназ | |
| RU2324684C2 (ru) | Пиримидиновые производные | |
| RU2207341C2 (ru) | Новые циклические соединения диамина, содержащие их лекарственные средства и способы лечения | |
| JP2017511360A5 (enExample) | ||
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| AR045040A1 (es) | Derivados de compuestos espiroazabiciclicos, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos | |
| RU2005116254A (ru) | Производные пиридопирролизина и пиридоиндолизина | |
| RU2003110577A (ru) | Гетероциклические соединения, связывающиеся с хемокиновыми рецепторами | |
| RU2005140570A (ru) | Фармацевтическая композиция, содержащая ингибитор гистондеацетилазы | |
| BR112014019478A2 (pt) | composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmacologicamente aceitável do mesmo, formulação inibidor do canal de sódio, métodos para tratamento e/ou prevenção de dor e de uma doença. | |
| RU2010116253A (ru) | Производные n-гидроксилсульфонамида как новые физиологически применимые доноры нитроксила | |
| AR069772A1 (es) | Derivados heterociclicos, una composicion farmaceutica y un juego que los comprenden y su uso en la preparacion de un medicamento para el tratamiento de una infeccion parasitaria. | |
| AR053195A1 (es) | Compuestos inhibidores de dipeptidil peptidasa-iv metodos para preparar los mismos y composiciones farmaceuticas que los contienen como un agente activo | |
| CA2694270A1 (en) | Substituted aryloxazoles and the use thereof | |
| RU2018127728A (ru) | Слитые трициклические гетероциклические соединения в качестве ингибиторов интегразы вич | |
| NO20030624L (no) | Cinnolinforbindelser | |
| RU2006132071A (ru) | Производные антраниловой кислоты, способы их получения и применение | |
| RU2008126245A (ru) | Комбинация ингибитора асне и антагониста 5-нт для лечения когнитивной дисфункции | |
| RU2006130000A (ru) | Органические соединения | |
| RU2019116590A (ru) | Трициклические гетероциклические соединения, полезные в качестве ингибиторов интегразы вич | |
| UY29312A1 (es) | Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20121006 |